Sviatlana Starchenka, Kemi Oluwayi, Matthew Heath, Oliver Armfield, Mohamed Shamji, Janice Layhadi, Katarzyna Lis, Lisa Cadavez, Olesya Rusyn, Murray Skinner, Pieter-Jan De Kam
INTRODUCTION: Allergen-specific immunotherapy (AIT) is the only disease-modifying treatment in allergic airway diseases. Underlying immunological mechanisms and candidate biomarkers, which may be translated into predictive/surrogate measures of clinical efficacy, remain an active area of research. The aim of this study was to evaluate Pollinex Quattro (PQ) Grass AIT induced immunomodulatory mechanisms, based on transcriptome profiling of peripheral blood mononuclear cells. METHODS: 119 subjects with grass pollen induced seasonal allergic rhinitis (SAR) were randomized in a 2:2:1:1 ratio to receive a cumulative dose of PQ Grass as a conventional or extended pre-seasonal regimen, placebo, or placebo with MicroCrystalline Tyrosine...
January 2, 2024: Clinical and Experimental Allergy